ReviewCurrent neuropharmacology2016
Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior.
Review in Current neuropharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Different Changes in Adipokines, Lipid Profile, and TNF-Alpha Levels between 10 and 20 Whole Body Cryostimulation Sessions in Individuals with I and II Degrees of Obesity.Biomedicines · 2022Article
- The anorexic effect of DL-fenfluramine is dependent on animals' habituation to different food types.Frontiers in integrative neuroscience · 2022Article
- Expansion and application of dye tracers for measuring solid food intake and food preference in Drosophila.Scientific reports · 2021Article
- Effects of Tyrosine and Tryptophan Supplements on the Vital Indicators in Mice Differently Prone to Diet-Induced Obesity.International journal of molecular sciences · 2021Article
- Effects of Tyrosine and Tryptophan in Rats with Diet-Induced Obesity.International journal of molecular sciences · 2021Article
- Negative Modulation of the Metabotropic Glutamate Receptor Type 5 as a Potential Therapeutic Strategy in Obesity and Binge-Like Eating Behavior.Frontiers in neuroscience · 2021Article
- Internal States Influence the Representation and Modulation of Food Intake by Subthalamic Neurons.Neuroscience bulletin · 2020Article
- Impacts of exercise intervention on various diseases in rats.Journal of sport and health science · 2020Review
- Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes.Science translational medicine · 2020Article
- Ginseng and obesity.Journal of ginseng research · 2018Review
- Suppressing effect of COR659 on alcohol, sucrose, and chocolate self-administration in rats: involvement of the GABAPsychopharmacology · 2017Article
- Analysis of the Relationship between Sleep Duration and Body Mass Index in a South Korean Adult Population: A Propensity Score Matching Approach.Journal of lifestyle medicine · 2017Article
- Polymorphisms of the oxytocin receptor gene and overeating: the intermediary role of endophenotypic risk factors.Nutrition & diabetes · 2017Article
- Effects of various ginsenosides and ginseng root and ginseng berry on the activity of Pancreatic lipase.Food science and biotechnology · 2017Article
- Comparative Study on the Effects of Ginseng and Green Tea Extracts on Selected Lipid Metabolism Markers in Adipocyte.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive intake of food, especially palatable and energy-dense carbohydrates and fats, is largely responsible for the growing incidence of obesity worldwide. Although there are a number of candidate antiobesity drugs, only a few of them have been proven able to inhibit appetite for palatable foods without the concurrent reduction in regular food consumption. In this review, we discuss the interrelationships between homeostatic and hedonic food intake control mechanisms in promoting overeating with palatable foods and assess the potential usefulness of systemically administered pharmaceuticals that impinge on the endogenous cannabinoid, opioid, aminergic, cholinergic, and peptidergic systems in the modification of food preference behavior. Also, certain dietary supplements with the potency to reduce specifically palatable food intake are presented. Based on human and animal studies, we indicate the most promising therapies and agents that influence the effectiveness of appetite-modifying drugs. It should be stressed, however, that most of the data included in our review come from preclinical studies; therefore, further investigations aimed at confirming the effectiveness and safety of the aforementioned medications in the treatment of obese humans are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.